NCT03128489View on ClinicalTrials.gov

Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

December 1, 2017

Primary Completion Date

August 1, 2018

Study Completion Date

August 1, 2018

Conditions

DiphtheriaAcellular PertussisHaemophilus Influenzae Type bTetanusPoliomyelitis

Interventions

BIOLOGICAL

Infanrix-IPV/Hib

Subjects will receive (Infanrix-IPV/Hib) as three-dose primary vaccination course at 6, 10 and 14 weeks of age. The vaccine will be administered intramuscularly, at a 90-degree angle into the anterolateral side of the thigh on the right side. The vaccine should not be administered in the buttock.